Chang WH - Search Results

1

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.

Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. J Clin Psychopharmacol. 2005 Feb;25(1):6-11. doi: 10.1097/01.jcp.0000150226.84371.76. J Clin Psychopharmacol. 2005. PMID: 15643094 Clinical Trial.

2

Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.

Lane HY, Chang YC, Su MH, Chiu CC, Huang MC, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. J Clin Psychopharmacol. 2002 Feb;22(1):4-10. doi: 10.1097/00004714-200202000-00002. J Clin Psychopharmacol. 2002. PMID: 11799336

3

Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics.

Lane HY, Chang YC, Chiu CC, Chen TT, Lee SH, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. J Clin Psychopharmacol. 2002 Aug;22(4):353-8. doi: 10.1097/00004714-200208000-00004. J Clin Psychopharmacol. 2002. PMID: 12172333

4

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.

Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. Am J Psychiatry. 2002 Sep;159(9):1593-5. doi: 10.1176/appi.ajp.159.9.1593. Am J Psychiatry. 2002. PMID: 12202283

5

Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.

Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. J Clin Psychiatry. 2003 Mar;64(3):316-20. doi: 10.4088/jcp.v64n0314. J Clin Psychiatry. 2003. PMID: 12716274 Clinical Trial.

6

Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.

Lane HY, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. Psychopharmacology (Berl). 2004 Apr;172(4):393-9. doi: 10.1007/s00213-003-1685-6. Epub 2003 Dec 9. Psychopharmacology (Berl). 2004. PMID: 14663551 Clinical Trial.

7

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.

Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. Schizophr Res. 2004 Mar 1;67(1):63-70. doi: 10.1016/j.schres.2003.08.006. Schizophr Res. 2004. PMID: 14741325 Clinical Trial.

8

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.

Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. Int J Neuropsychopharmacol. 2004 Dec;7(4):461-70. doi: 10.1017/S1461145704004389. Epub 2004 May 12. Int J Neuropsychopharmacol. 2004. PMID: 15140279 Free article. Clinical Trial.

9

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.

Lane HY, Lee CC, Liu YC, Chang WH. Lane HY, et al. Among authors: chang wh. Pharmacogenomics. 2005 Mar;6(2):139-49. doi: 10.1517/14622416.6.2.139. Pharmacogenomics. 2005. PMID: 15882132 Review.

10

Risperidone-related weight gain: genetic and nongenetic predictors.

Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH. Lane HY, et al. Among authors: chang wh, chang yc. J Clin Psychopharmacol. 2006 Apr;26(2):128-34. doi: 10.1097/01.jcp.0000203196.65710.2b. J Clin Psychopharmacol. 2006. PMID: 16633140 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,306 results

Search Page